CL2021001973A1 - Compuesto heterocíclico y su uso. - Google Patents

Compuesto heterocíclico y su uso.

Info

Publication number
CL2021001973A1
CL2021001973A1 CL2021001973A CL2021001973A CL2021001973A1 CL 2021001973 A1 CL2021001973 A1 CL 2021001973A1 CL 2021001973 A CL2021001973 A CL 2021001973A CL 2021001973 A CL2021001973 A CL 2021001973A CL 2021001973 A1 CL2021001973 A1 CL 2021001973A1
Authority
CL
Chile
Prior art keywords
heterocyclic compound
receptor agonist
activity
orexin type
narcolepsy
Prior art date
Application number
CL2021001973A
Other languages
English (en)
Inventor
Yasushi Hattori
Takahiro Sugimoto
Tsuneo Oda
Yuichi Kajita
Yuhei Miyanohana
Tatsuki Koike
Kohei Takeuchi
Yoshiteru Ito
Norihito Tokunaga
Yasutaka Hoashi
Keisuke Imamura
Alexander Martin Pawliczek
Tohru Miyazaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2021001973A1 publication Critical patent/CL2021001973A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente proporciona un compuesto heterocíclico que tiene actividad de un agonista del receptor de orexina tipo 2. Un compuesto representado por la fórmula (I), en donde cada símbolo es como se describe en la memoria descriptiva, o una de sus sales tiene una actividad del agonista del receptor de orexina tipo 2, y es útil como un agente para la profilaxis o tratamiento de la narcolepsia
CL2021001973A 2019-01-31 2021-07-27 Compuesto heterocíclico y su uso. CL2021001973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019015488 2019-01-31

Publications (1)

Publication Number Publication Date
CL2021001973A1 true CL2021001973A1 (es) 2022-04-08

Family

ID=69770989

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001973A CL2021001973A1 (es) 2019-01-31 2021-07-27 Compuesto heterocíclico y su uso.

Country Status (20)

Country Link
US (3) US11028048B2 (es)
EP (1) EP3917616A1 (es)
JP (2) JP7253640B2 (es)
KR (1) KR20210121080A (es)
CN (6) CN118271298A (es)
AR (1) AR117916A1 (es)
AU (1) AU2020215380A1 (es)
BR (1) BR112021014180A2 (es)
CA (1) CA3124536A1 (es)
CL (1) CL2021001973A1 (es)
CO (1) CO2021011188A2 (es)
EA (1) EA202192138A1 (es)
EC (1) ECSP21056325A (es)
IL (1) IL284073A (es)
MX (1) MX2021008241A (es)
PE (1) PE20211700A1 (es)
SG (1) SG11202106791XA (es)
TW (1) TWI832962B (es)
WO (1) WO2020158958A1 (es)
ZA (1) ZA202106304B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020394444A1 (en) 2019-11-25 2022-05-19 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
EP4066893A4 (en) 2019-11-27 2023-12-20 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
IL300610A (en) 2020-08-18 2023-04-01 Merck Sharp ַ& Dohme Llc Bicycloheptane pyrrolidine compounds are orexin receptor agonists
JP2023540344A (ja) * 2020-09-03 2023-09-22 センテッサ ファーマシューティカルズ （オレキシア） リミテッド 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
US20230331720A1 (en) * 2020-09-03 2023-10-19 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
JP7511087B2 (ja) * 2020-11-02 2024-07-08 メルク・シャープ・アンド・ドーム・エルエルシー 大環状尿素オレキシン受容体アゴニスト
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) * 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
BR112023020104A2 (pt) 2021-04-02 2023-11-14 Takeda Pharmaceuticals Co Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides
TW202400606A (zh) 2022-03-01 2024-01-01 英商歐瑞夏治療公司 中環或大環之經苄基取代之雜環衍生物及相關用途
WO2023199091A1 (en) 2022-04-12 2023-10-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW202428580A (zh) 2022-10-31 2024-07-16 日商武田藥品工業股份有限公司 雜環化合物
WO2024095158A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
US20240217957A1 (en) 2022-11-30 2024-07-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2024128305A1 (ja) * 2022-12-16 2024-06-20 第一三共株式会社 ２－アザビシクロ［３．１．１］ヘプタン化合物
US20240309016A1 (en) 2023-03-16 2024-09-19 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
WO2001000665A2 (en) 1999-06-28 2001-01-04 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
EP1252329A4 (en) 1999-07-30 2004-12-22 Univ Leland Stanford Junior HYPOCRETINE AND HYPOCRETINE RECEPTORS FOR THE REGULATION OF SLEEP AND SLEEP DISORDERS
US7112566B1 (en) 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
AU2001251306A1 (en) 2000-04-04 2001-10-15 Siegel, Jerome M. Treatment of sleep disorders with hypocretin-1
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
ES2303912T3 (es) 2002-12-13 2008-09-01 Janssen Pharmaceutica Nv Metodo para identificar moduladores del receptor de orexina-2 humano.
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
JP5232987B2 (ja) 2006-04-14 2013-07-10 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールオキシエチルアミン化合物
AU2012200270A1 (en) * 2007-05-23 2012-02-09 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2009049215A1 (en) 2007-10-10 2009-04-16 Wake Forest University Health Sciences Methods to reduce the effects of sleep deprivation
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2012137982A2 (en) 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201341380A (zh) * 2012-04-05 2013-10-16 Takeda Pharmaceutical 磺醯胺衍生物及其用途
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
BR112016013299A2 (pt) 2013-12-12 2017-08-08 Univ Tsukuba Composto
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
EP3029024A1 (en) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
JP6746107B2 (ja) 2015-02-19 2020-08-26 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
JP6775803B2 (ja) 2015-06-12 2020-10-28 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
PT3411358T (pt) * 2016-02-04 2022-01-19 Takeda Pharmaceuticals Co Composto de piperidina substituído e a sua utilização
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
UA125597C2 (uk) * 2017-08-03 2022-04-27 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука та її застосування
JP7189140B2 (ja) 2017-08-03 2022-12-13 武田薬品工業株式会社 複素環化合物およびその用途
WO2019112007A1 (ja) 2017-12-07 2019-06-13 国立大学法人 筑波大学 鎮痛薬による眠気の予防または治療薬
WO2020004536A1 (ja) 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020004537A1 (ja) 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020122092A1 (ja) 2018-12-12 2020-06-18 武田薬品工業株式会社 複素環化合物
US12091410B2 (en) 2018-12-12 2024-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
US20210276949A1 (en) 2021-09-09
IL284073A (en) 2021-08-31
US11028048B2 (en) 2021-06-08
US20200247747A1 (en) 2020-08-06
KR20210121080A (ko) 2021-10-07
JP2023078426A (ja) 2023-06-06
CN118271297A (zh) 2024-07-02
JP2022519331A (ja) 2022-03-22
PE20211700A1 (es) 2021-09-01
CO2021011188A2 (es) 2021-10-29
CN118420600A (zh) 2024-08-02
JP7253640B2 (ja) 2023-04-06
CN118271298A (zh) 2024-07-02
ZA202106304B (en) 2023-06-28
CN118344346A (zh) 2024-07-16
CN113395993B (zh) 2024-02-20
ECSP21056325A (es) 2021-09-30
EP3917616A1 (en) 2021-12-08
TWI832962B (zh) 2024-02-21
AU2020215380A2 (en) 2021-08-19
CN113395993A (zh) 2021-09-14
US20230040770A1 (en) 2023-02-09
JP7502512B2 (ja) 2024-06-18
BR112021014180A2 (pt) 2021-09-21
MX2021008241A (es) 2021-08-16
CA3124536A1 (en) 2020-08-06
WO2020158958A1 (en) 2020-08-06
CN118290408A (zh) 2024-07-05
AR117916A1 (es) 2021-09-01
TW202043196A (zh) 2020-12-01
AU2020215380A1 (en) 2021-08-19
SG11202106791XA (en) 2021-07-29
EA202192138A1 (ru) 2022-03-10

Similar Documents

Publication Publication Date Title
CL2021001973A1 (es) Compuesto heterocíclico y su uso.
CO2020001879A2 (es) Compuesto heterocíclico y su uso
CO2018008705A2 (es) Compuestos de piperidina sustituido y su uso
CO2019007032A2 (es) Dinucleótido cíclico como agonistas de sting (estimulador de genes de interferón)
AR111346A1 (es) Compuesto peptídico con acción activante sobre receptores gip
UY37494A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
GT201300152A (es) Amidas aminoindanes con una alta actividad fungicida y sus composiciones fitosanitarias
CO2019012125A2 (es) Inhibidores ip6k
UY31781A (es) Derivados de iminopiridina y su uso
UY37647A (es) Amidas de ácido n–(1,3,4–oxadiazol–2–il)arilcarboxílico sustituidas y su compuesto como herbicidas
CL2017000105A1 (es) Novedosas pirimidinas 2,5-sustituidas.
AR113270A1 (es) Compuesto de heteroarilo con contenido de nitrógeno y su uso farmacéutico
CL2021001246A1 (es) Moduladores de expresión irf5.
BR112016021171B8 (pt) processo para fabricação de composto oticamente ativo
AR070874A1 (es) Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
UY38472A (es) Moduladores de la expresión de foxp3
CO2020003134A2 (es) Moduladores de la expresión de enac
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CO2019012270A2 (es) Compuesto heterocíclico
AR109405A1 (es) Compuestos de fenilurea y su uso
CO2019012295A2 (es) Compuesto heterocíclico
EA202090428A1 (ru) Гетероциклическое соединение и его применение
CO2020012101A2 (es) Compuesto heterocíclico
AR117079A1 (es) Moduladores de la expresión de foxp3
PL419661A1 (pl) Borofunkcyjne disilazany